Literature DB >> 16223888

Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension.

Thomas Mueller1, Alfons Gegenhuber, Benjamin Dieplinger, Werner Poelz, Meinhard Haltmayer.   

Abstract

BACKGROUND: The aim of the present study was to prospectively evaluate the diagnostic utility of B-type natriuretic peptide (BNP) and amino-terminal proBNP (NT-proBNP) measurements for the detection of cardiac structural disease in asymptomatic patients with systemic arterial hypertension and to test the hypothesis that the 2 analytes are equally useful in this clinical setting.
METHODS: We studied a consecutive series of 149 asymptomatic patients referred for echocardiographic evaluation of the cardiac effects of systemic arterial hypertension. Diagnosis of cardiac structural disease was based on the presence of systolic or diastolic dysfunction, left atrial dilatation, left ventricular dilatation or hypertrophy, pulmonary hypertension, and wall motion or valvular abnormalities. Blood concentrations of BNP and NT-proBNP were measured by 2 commercially available assays (Abbott AxSYM and Roche Elecsys, respectively). Diagnostic accuracies of BNP and NT-proBNP were assessed by ROC curve analysis. Areas under the curves were compared by analysis of equivalency.
RESULTS: In distinguishing between hypertensive patients with cardiac structural disease (n = 118) and hypertensive patients without (n = 31), areas under the curves were 0.740 (95% confidence interval, 0.662-0.808) for BNP and 0.762 (0.685-0.828) for NT-proBNP and were significantly equivalent (P = 0.015). Cutoff values with a 90% sensitivity for cardiac structural disease were 17 ng/L for BNP and 39 ng/L for NT-proBNP, with 29% and 32% specificity, respectively.
CONCLUSIONS: BNP and NT-proBNP have similar capabilities for detecting cardiac structural disease in asymptomatic patients with systemic arterial hypertension. However, in the setting evaluated, a screening strategy relying on measurement of BNP or NT-proBNP may be of limited value because of the low specificity at the selected cutoff values.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223888     DOI: 10.1373/clinchem.2005.056648

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Midregional pro-adrenomedullin and copeptin: exercise kinetics and association with the cardiopulmonary exercise response in comparison to B-type natriuretic peptide.

Authors:  Marzena Zurek; Micha T Maeder; Martin H Brutsche; Adrian Lüthi; Raphael Twerenbold; Michael Freese; Hans Rickli; Christian Mueller
Journal:  Eur J Appl Physiol       Date:  2014-01-05       Impact factor: 3.078

Review 2.  Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.

Authors:  Farah Omran; Ioannis Kyrou; Faizel Osman; Ven Gee Lim; Harpal Singh Randeva; Kamaljit Chatha
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

3.  Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care.

Authors:  John Gierula; Richard M Cubbon; Maria F Paton; Rowenna Byrom; Judith E Lowry; Sarah F Winsor; Melanie McGinlay; Emma Sunley; Emma Pickles; Lorraine C Kearney; Aaron Koshy; Thomas A Slater; Hemant K Chumun; Haqeel A Jamil; Kristian M Bailey; Julian H Barth; Mark T Kearney; Klaus K Witte
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-07-01

4.  Plasma protein thiolation index (PTI) as a potential biomarker for left ventricular hypertrophy in humans.

Authors:  Begoña Quintana-Villamandos; Irene González Del Pozo; Laia Pazó-Sayós; Jose María Bellón; Álvaro Pedraz-Prieto; Ángel G Pinto; Emilio Delgado-Baeza
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.